COMPANY

Canget Biotekpharma, LLC

HQ: Buffalo, NY source · canget-biotek.com ↗ · Mid-Atlantic

CANGET BIOTEKPHARMA, LLC has received NIH funding, most recently in fiscal 2023 for the project “Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials”. From public records Source · Oct 12, 2026

Keywords: cancer

Profile checked Oct 10, 2026

6NIH grants

NIH awards 6

Annual award amounts. Total $3.0M.

Sep 12, 2023 NIH award 1R43CA275410-01A1 FY2023: $400,000 awarded for that fiscal year; activity R43 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. Perform non-GLP and GLP TOX/TK studies, and source ↗
Aug 16, 2018 NIH award 3R44CA176937-03S1 FY2018: $210,000 awarded for that fiscal year; activity R44 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. A small molecule broad spectrum inhibitor o source ↗
Aug 14, 2018 NIH award 1R43CA221389-01A1 FY2018: $224,919 awarded for that fiscal year; activity R43 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. A novel small molecule FL7N-1 for treating source ↗
Aug 1, 2016 NIH award 5R44CA176937-03 FY2016: $988,326 awarded for that fiscal year; activity R44 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. A small molecule broad spectrum inhibitor of source ↗
Sep 2, 2015 NIH award 4R44CA176937-02 FY2015: $903,055 awarded for that fiscal year; activity R44 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. A small molecule broad spectrum inhibitor of source ↗
Jul 22, 2014 NIH award 1R44CA176937-01A1 FY2014: $224,988 awarded for that fiscal year; activity R44 (SBIR); PI LING, XIANG; recipient as written: CANGET BIOTEKPHARMA, LLC, BUFFALO, NY. A small molecule broad spectrum inhibitor o source ↗